{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:49:09Z","timestamp":1774993749693,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[1999,10,1]],"date-time":"1999-10-01T00:00:00Z","timestamp":938736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[1999,10]]},"DOI":"10.1053\/beem.1999.0030","type":"journal-article","created":{"date-parts":[[2002,7,28]],"date-time":"2002-07-28T17:49:59Z","timestamp":1027878599000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Clinical management of prolactinomas"],"prefix":"10.1053","volume":"13","author":[{"given":"Jonathan","family":"Webster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/beem.1999.0030_RF1","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1159\/000126575","article-title":"Graded hyperprolactinemia first suppresses LH pulse frequency and then pulse amplitude in castrated male rats","volume":"58","author":"Park","year":"1993","journal-title":"Neuroendocrinology"},{"key":"10.1053\/beem.1999.0030_RF2","series-title":"Endocrine Neoplasms","first-page":"41","article-title":"Prolactinomas","author":"Katznelson","year":"1997"},{"key":"10.1053\/beem.1999.0030_RF3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.7326\/0003-4819-112-12-925","article-title":"The pituitary \u2018incidentaloma\u2019","volume":"112","author":"Molitch","year":"1990","journal-title":"Annals of Internal Medicine"},{"key":"10.1053\/beem.1999.0030_RF5","first-page":"117","article-title":"Diagnosis and treatment of prolactinomas","volume":"44","author":"Molitch","year":"1999","journal-title":"Advances in Internal Medicine"},{"key":"10.1053\/beem.1999.0030_RF6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","article-title":"Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women","volume":"44","author":"Crosignani","year":"1992","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1053\/beem.1999.0030_RF7","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1056\/NEJM198505233122106","article-title":"Pregnancy and the hyperprolactinemic woman","volume":"312","author":"Molitch","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.1999.0030_RF8","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","article-title":"Long-term follow-up of patients with hyperprolactinaemia","volume":"45","author":"Jeffcoate","year":"1996","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF9","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/oxfordjournals.humrep.a137010","article-title":"Is pregnancy the best treatment for hyperprolactinaemia?","volume":"4","author":"Crosignani","year":"1989","journal-title":"Human Reproduction"},{"key":"10.1053\/beem.1999.0030_RF10","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJM198012253032605","article-title":"Decreased bone density in hyperprolactinemic women","volume":"303","author":"Klibanski","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.1999.0030_RF11","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1210\/jcem-56-6-1120","article-title":"Bone density in amenorrheic women with and without hyperprolactinemia","volume":"56","author":"Schlechte","year":"1983","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF12","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.1984.03340290040017","article-title":"Decreased spinal mineral content in amenorrheic women","volume":"251","author":"Cann","year":"1984","journal-title":"Journal of the American Medical Association"},{"key":"10.1053\/beem.1999.0030_RF13","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1210\/jcem-59-6-1050","article-title":"Vertebral body bone mineral content in hyperprolactinemic women","volume":"59","author":"Koppelman","year":"1984","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJM198608283150903","article-title":"Increase in bone mass after treatment of hyperprolactinemic amenorrhea","volume":"315","author":"Klibanski","year":"1986","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.1999.0030_RF15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1210\/jcem-64-5-1021","article-title":"Forearm and vertebral bone mineral density in treated and untreated hyperprolactinemic amenorrhea","volume":"64","author":"Schlechte","year":"1987","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF16","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-67-1-124","article-title":"Effects of prolactin and estrogen deficiency in amenorrheic bone loss","volume":"67","author":"Klibanski","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF17","first-page":"698","article-title":"A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia","volume":"75","author":"Schlechte","year":"1992","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF18","first-page":"692","article-title":"Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea","volume":"75","author":"Biller","year":"1992","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-104-6-777","article-title":"Osteoporosis in men with hyperprolactinemic hypogonadism","volume":"104","author":"Greenspan","year":"1986","journal-title":"Annals of Internal Medicine"},{"key":"10.1053\/beem.1999.0030_RF20","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","article-title":"Bone markers and bone density responses to dopamine agonist therapy in hyperprolactinemic males","volume":"83","author":"Di Somma","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF21","doi-asserted-by":"crossref","DOI":"10.1046\/j.1365-2265.2000.00902.x","article-title":"Prolactinomas in children and adolescents: persistent bone loss after 2 years of prolactin normalization","author":"Colao","year":"2000","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF22","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1210\/jcem.82.8.4188","article-title":"Extensive surgical experience. Surgical management of pituitary tumors","volume":"82","author":"Wilson","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF23","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00006123-199902000-00006","article-title":"Transsphenoidal microsurgical therapy of prolactinomas: initial outcomes and long-term results","volume":"44","author":"Tyrrell","year":"1999","journal-title":"Neurosurgery"},{"key":"10.1053\/beem.1999.0030_RF24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2265.1992.tb02900.x","article-title":"Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests","volume":"36","author":"Webster","year":"1992","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF25","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S0889-8529(18)30193-2","article-title":"Pathologic hyperprolactinemia","volume":"21","author":"Molitch","year":"1992","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"10.1053\/beem.1999.0030_RF26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0090-3019(95)00430-0","article-title":"Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow up","volume":"45","author":"Massoud","year":"1996","journal-title":"Surgical Neurology"},{"key":"10.1053\/beem.1999.0030_RF27","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2265.1987.tb00809.x","article-title":"Factors in the outcome of transsphenoidal surgery for prolactinoma and non-functioning pituitary tumour, including preoperative bromocriptine therapy","volume":"26","author":"Bevan","year":"1986","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF28","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2265.1996.738559.x","article-title":"The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy","volume":"44","author":"Soule","year":"1996","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1530\/eje.0.1400043","article-title":"Trans-sphenoidal surgery for microprolactinoma: an acceptable alternative to dopamine agonists?","volume":"140","author":"Turner","year":"1999","journal-title":"European Journal of Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/255497a0","article-title":"Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells","volume":"255","author":"Lloyd","year":"1975","journal-title":"Nature"},{"key":"10.1053\/beem.1999.0030_RF31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1210\/jcem-66-1-193","article-title":"Prolactin-lowering effect of acute and once weekly repetive oral administration of cabergoline at two dose levels in hyperprolactinemic patients","volume":"66","author":"Mattei","year":"1988","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1056\/NEJM199410063311403","article-title":"A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea","volume":"331","author":"Webster","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.1999.0030_RF33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2265.1997.1300952.x","article-title":"Treatment of macroprolactinomas with cabergoline: a study of 85 patients","volume":"46","author":"Ferrari","year":"1997","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF34","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1210\/edrv-13-2-220","article-title":"Dopamine agonists and pituitary tumor shrinkage","volume":"13","author":"Bevan","year":"1992","journal-title":"Endocrine Reviews"},{"key":"10.1053\/beem.1999.0030_RF35","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1210\/jcem-69-3-500","article-title":"Resistance to bromocriptine in prolactinomas","volume":"69","author":"Pellegrini","year":"1989","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF36","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000126764","article-title":"Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas","volume":"60","author":"Caccavelli","year":"1994","journal-title":"Neuroendocrinology"},{"key":"10.1053\/beem.1999.0030_RF37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2165\/00002018-199614040-00003","article-title":"A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"14","author":"Webster","year":"1996","journal-title":"Drug Safety"},{"key":"10.1053\/beem.1999.0030_RF38","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1210\/jcem-72-3-635","article-title":"A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia","volume":"72","author":"Lamberts","year":"1991","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF39","first-page":"39","article-title":"Control of hyperprolactinemia with pergolide","volume":"30","author":"Mattox","year":"1986","journal-title":"International Journal of Fertility"},{"key":"10.1053\/beem.1999.0030_RF40","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/bmj.294.6583.1323-a","article-title":"Clinical evaluation of lysuride in the management of hyperprolactinaemia","volume":"294","author":"Bouloux","year":"1987","journal-title":"British Medical Journal (Clinical Research Edition)"},{"key":"10.1053\/beem.1999.0030_RF41","first-page":"115","article-title":"Metergoline as an inhibitor of prolactin release","volume":"32","author":"Caballero","year":"1987","journal-title":"Journal of Reproductive Medicine"},{"key":"10.1053\/beem.1999.0030_RF42","first-page":"225","article-title":"Suppression of puerperal lactation by terguride. A double-blind study","volume":"19","author":"Venturini","year":"1988","journal-title":"Gynecologic and Obstetric Investigation"},{"key":"10.1053\/beem.1999.0030_RF43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/09513598809029341","article-title":"Dihydroergocristine in stopping lactation: double blind study vs bromocriptine","volume":"2","author":"De Aloysio","year":"1988","journal-title":"Gynecological Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF44","doi-asserted-by":"crossref","first-page":"255","DOI":"10.2165\/00003495-199549020-00009","article-title":"Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation","volume":"49","author":"Rains","year":"1995","journal-title":"Drugs"},{"key":"10.1053\/beem.1999.0030_RF45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1365-2265.1992.tb01485.x","article-title":"Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study","volume":"37","author":"Webster","year":"1992","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF46","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.1993.tb02372.x","article-title":"The efficacy and tolerability of cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled multicentre study","volume":"39","author":"Webster","year":"1993","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF47","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1210\/jcem.82.11.4368","article-title":"Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage","volume":"82","author":"Colao","year":"1997","journal-title":"Journal of Clinical Endocrinology Metabolism"},{"key":"10.1053\/beem.1999.0030_RF48","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline","volume":"81","author":"Biller","year":"1996","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF49","first-page":"287","article-title":"Effects of two novel dopaminergic drugs, CV 205-502 and CQP 201-403, on prolactin and growth hormone secretion by human pituitary tumours in vitro","volume":"116","author":"Venetikou","year":"1987","journal-title":"Acta Endocrinologica"},{"key":"10.1053\/beem.1999.0030_RF50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2265.1987.tb00789.x","article-title":"CV 205-502: a new long-acting drug for inhibition of prolactin hypersecretion","volume":"26","author":"Rasmussen","year":"1987","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF51","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","article-title":"A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia","volume":"32","author":"Homburg","year":"1990","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF52","first-page":"385","article-title":"Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: a double blind study","volume":"125","author":"Verhelst","year":"1991","journal-title":"Acta Endocrinologica"},{"key":"10.1053\/beem.1999.0030_RF53","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0028-2243(91)90101-P","article-title":"CV 205-502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia","volume":"40","author":"van der Heijden","year":"1991","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1053\/beem.1999.0030_RF54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/BF03344963","article-title":"A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients","volume":"17","author":"Giusti","year":"1994","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1053\/beem.1999.0030_RF55","first-page":"1","article-title":"Quinagolide in hyperprolactinaemia","volume":"9","author":"Brownell","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1053\/beem.1999.0030_RF56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1530\/eje.0.1350548","article-title":"Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinaemic males","volume":"135","author":"Colao","year":"1996","journal-title":"European Journal of Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF57","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1111\/j.1365-2265.1994.tb02799.x","article-title":"Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine","volume":"41","author":"Vilar","year":"1994","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF58","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3109\/09513599409072452","article-title":"Positive response to compound CV 205-502 in hyperprolactinaemic patients resistant to or intolerant of bromocriptine","volume":"8","author":"Merola","year":"1994","journal-title":"Gynecological Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF59","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1159\/000182739","article-title":"The effects of CV 205-502 in patients with hyperprolactinaemia intolerant and\/or resistant to bromocriptine","volume":"39","author":"Razzaq","year":"1993","journal-title":"Hormone Research"},{"key":"10.1053\/beem.1999.0030_RF60","first-page":"489","article-title":"Cabergoline in the long-term therapy of hyperprolactinemic disorders","volume":"126","author":"Ferrari","year":"1992","journal-title":"Acta Endocrinologica"},{"key":"10.1053\/beem.1999.0030_RF61","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1471-0528.1994.tb13626.x","article-title":"Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility","volume":"101","author":"Jones","year":"1994","journal-title":"British Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beem.1999.0030_RF62","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3109\/01443618909151142","article-title":"Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient","volume":"10","author":"Page","year":"1989","journal-title":"Journal of Obstetrics and Gynaecology"},{"key":"10.1053\/beem.1999.0030_RF63","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1210\/jcem-69-4-725","article-title":"Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients","volume":"69","author":"Ciccarelli","year":"1989","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF64","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1530\/eje.0.1340454","article-title":"Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine","volume":"134","author":"Delgrange","year":"1996","journal-title":"European Journal of Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1530\/eje.0.1350413","article-title":"Prolactinomas resistant to bromocriptine: long-term efficacy of quinagolide and outcome of pregnancy","volume":"134","author":"Morange","year":"1996","journal-title":"European Journal of Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF66","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","article-title":"Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up","volume":"83","author":"Colao","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF67","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","article-title":"Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline therapy","volume":"82","author":"Colao","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF68","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1210\/jcem.82.8.4178-2","article-title":"Prolactinomas apparently resistant to standard dopamine agonists respond to chronic cabergoline therapy","volume":"82","author":"Delgrange","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF69","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1210\/jcem.82.8.4178-3","article-title":"Prolactinomas apparently resistant to standard dopamine agonists respond to chronic cabergoline therapy","volume":"82","author":"Colao","year":"1997","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF70","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1210\/jcem-53-3-480","article-title":"Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine","volume":"53","author":"Thorner","year":"1981","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1053\/beem.1999.0030_RF71","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","article-title":"Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas","volume":"ii","author":"Johnson","year":"1984","journal-title":"Lancet"},{"key":"10.1053\/beem.1999.0030_RF72","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","article-title":"Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size","volume":"34","author":"Van't Verlaat","year":"1991","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF73","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1365-2265.1991.tb00288.x","article-title":"Should dopamine agonist treatment for prolactinomas be life-long?","volume":"34","author":"Faglia","year":"1991","journal-title":"Clinical Endocrinology"},{"key":"10.1053\/beem.1999.0030_RF74","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1056\/NEJM198509123131103","article-title":"Low doses of dopamine agonists in the long-term treatment of macroprolactinomas","volume":"313","author":"Liuzzi","year":"1985","journal-title":"New England Journal of Medicine"},{"key":"10.1053\/beem.1999.0030_RF75","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long term treatment of hyperprolactinemic and acromegalic patients","volume":"20","author":"Muratori","year":"1997","journal-title":"Journal of Endocrinological Investigation"},{"key":"10.1053\/beem.1999.0030_RF78","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S0015-0282(16)55819-1","article-title":"The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinoemia","volume":"59","author":"Corenblum","year":"1993","journal-title":"Fertility and Sterility"},{"key":"10.1053\/beem.1999.0030_RF79","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0010-7824(98)00069-9","article-title":"Two-year treatment with oral contraceptives in hyperprolactinemic patients","volume":"58","author":"Testa","year":"1998","journal-title":"Contraception"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X99900301?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X99900301?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:33:49Z","timestamp":1761496429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X99900301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1999,10]]}},"alternative-id":["S1521690X99900301"],"URL":"https:\/\/doi.org\/10.1053\/beem.1999.0030","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical management of prolactinomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/beem.1999.0030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 1999 Harcourt Publishers Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}